North America Point-Of-Care Diagnostics Market – Industry Trends and Forecast to 2031

Analyse et taille du marché des diagnostics au point de service en Amérique du Nord

Le marché des diagnostics au point d'intervention devrait connaître une croissance significative en raison de l'importance croissante de ces diagnostics dans la surveillance environnementale et la santé publique. L'augmentation du financement provenant de sources telles que le NIH, de fondations privées telles que la Fondation Bill & Melinda Gates et du ministère américain de la Défense a permis aux fabricants d'améliorer leurs capacités de production d'équipements de diagnostic au point d'intervention.

Data Bridge Market Research analyse le marché nord-américain du diagnostic au point de service, qui était de 18,62 milliards USD en 2023, et devrait atteindre 30,12 milliards USD d'ici 2031, à un TCAC de 6,20 % au cours de la période de prévision 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée du rapport et segmentation du marché      

Définition du marché

Les diagnostics au point de service sont des méthodes rapides et sensibles utilisées pour la détection précoce des infections. Ils offrent des solutions rentables pour les patients externes, les médecins, les laboratoires cliniques et les services de soins à domicile. Cette approche permet de prendre des décisions médicales rapides en facilitant le diagnostic précoce de la maladie, ce qui conduit à de meilleurs résultats de santé grâce à une mise en route rapide du traitement.

Dynamique du marché des diagnostics au point de service en Amérique du Nord

Conducteurs

• Les progrès technologiques offrent des capacités de diagnostic améliorées

Les innovations continues, telles que les appareils miniaturisés, les capteurs avancés et les biocapteurs de pointe, contribuent à une détection plus rapide et plus précise des maladies. Ces avancées technologiques permettent aux professionnels de la santé de disposer d'outils efficaces, permettant un diagnostic rapide sur place. À mesure que le paysage des points de service évolue, l'intégration de technologies de pointe améliore la précision des tests et soutient la croissance du marché en répondant à la demande croissante de solutions de diagnostic rapides et précises.

• L'augmentation de l'incidence des maladies infectieuses accroît le besoin de solutions de diagnostic rapide

L’incidence croissante des infections nécessite des solutions de diagnostic rapides et précises pour permettre une mise en route rapide du traitement. Les diagnostics au point de service offrent un moyen rapide et efficace de détecter les maladies, en particulier dans les régions où la charge de morbidité infectieuse est élevée. Cette demande croissante d’outils de diagnostic rapides et sur place fait avancer le marché, car les systèmes de santé recherchent des stratégies efficaces pour détecter et contenir précocement les menaces infectieuses.

Opportunités

• L’accent croissant mis sur les maladies non transmissibles accroît la croissance du marché du diagnostic

La prévalence des maladies chroniques telles que le diabète, les maladies cardiovasculaires et le cancer augmente, ce qui accroît le besoin d’outils de diagnostic rapides et accessibles. Les diagnostics au point de service offrent des moyens rapides et efficaces de détecter et de surveiller les maladies non transmissibles, permettant une intervention rapide et des stratégies de traitement personnalisées. Cette attention accrue portée aux maladies non transmissibles stimule la demande de solutions au point de service, contribuant à l’expansion du marché du diagnostic pour relever les défis posés par les maladies chroniques.

• La surveillance à distance des patients permet de réaliser certains tests à domicile 

Enabling individuals to conduct specific tests in the comfort of their homes, this approach enhances accessibility to healthcare. Remote monitoring devices, coupled with diagnostic capabilities, empower patients to conveniently perform tests, promoting early detection and proactive management of health conditions. This trend fosters patient engagement and contributes to the overall growth of the point-of-care diagnostics market by expanding its reach beyond traditional healthcare settings.

Restraints/Challenges

• Regulatory Challenges Effecting Seamless Operations

Stringent regulatory requirements and approval processes can lead to delays in product launches and market entry. Compliance complexities and evolving regulatory landscapes may pose hurdles for companies in achieving swift and efficient commercialization of point-of-care diagnostic technologies. These challenges may impact the market's growth by creating barriers to the timely introduction of innovative solutions and hindering the operational fluidity in the industry.

• Economic Constraints Limits the Affordability of Point-of-care Diagnostic Devices

The high initial costs and ongoing expenses associated with these advanced technologies may hinder their widespread adoption, particularly in resource-constrained settings. Limited financial resources within healthcare systems and among end-users could impede the accessibility of point-of-care diagnostic solutions, potentially slowing down market growth.

This North America point-of-care diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the North America point-of-care diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2023, QIAGEN achieved CE certification for its IVD kit and NeuMoDx automated testing platform. This certification significantly bolstered the company's market share and revenue, marking a positive stride in the adoption of their advanced diagnostic technologies
• In 2023, Danaher Corporation introduced the Dxl 9000 Access Immunoassay Analyzer, capable of running up to 215 tests per hour. This strategic initiative expanded Danaher's portfolio in the point-of-care diagnostics sector, emphasizing increased testing efficiency and contributing to the company's market presence
• In 2022, Genes2Me Pvt. Ltd launched the Rapi-Q Point of Care RT PCR solution, targeting human papillomavirus (HPV) and tuberculosis. The device, with CE-IVD marking, offers rapid results in less than 45 minutes, displaying superior performance, high sensitivity, and user-friendly features
• In 2022, LumiraDx Healthcare launched its highly sensitive C-Reactive Protein (CRP) point-of-care antigen test in India. This innovative diagnostic tool addresses clinical settings' needs, aiding in the reduction of unnecessary antibiotic prescribing to combat antimicrobial resistance (AMR)
• In 2022, Genes2Me Pvt. Ltd, also launched the Rapi-Q Point of Care RT PCR solution for HPV and tuberculosis. Featuring CE-IVD marking, this device stands out for its simplicity, delivering rapid results in under 45 minutes, coupled with superior sensitivity and stable detection capabilities

North America Point-Of-Care Diagnostics Market Scope

The North America point-of-care diagnostics market is segmented on the basis of product, platform, prescription and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Glucose Monitoring Products
• Strips
• Meters
• Lancets
• Lancing Device
• Cardio metabolic
• Cardiac marker
• Blood Gas
• Electrolytes
• HBA1C
• Infectious Disease
• Influenza
• HIV
• Hepatitis C
• Sexually Transmitted Disease (STD)
• Healthcare-Associated Infection (HAI)
• Respiratory Infection
• Tropical Disease
• Other Infectious Disease
• Coagulation
• PT or INR
• Activated clotting time (ACT or APTT)
• Pregnancy and Fertility
• Pregnancy Test
• Fertility Test
• Tumour or Cancer Marker
• Urinalysis
• Cholesterol
• Haematology
• Drugs-of-Abuse
• Fecal Occult
• Others

Platform

• Lateral Flow Assays
• Immunochromatography Tests
• Dipsticks
• Microfluidics
• Molecular Diagnostics
• Immunoassays

Prescription

• Prescription-Based Testing
• OTC Testing

End User

• Clinical Laboratories
• Outpatient Healthcare and Ambulatory Care Settings
• Hospitals or Critical Care Centres
• Home Care
•  Research Laboratories
• Others

North America Point-Of-Care Diagnostics Market Regional Analysis/Insights

The North America point-of-care diagnostics market is analyzed and market size insights and trends are provided by product, platform, prescription and end user as referenced above.

The major countries covered in the North America point-of-care diagnostics market report are U.S., Canada and Mexico

The U.S. is expected to grow with the CAGR in the forecast period, primarily attributed to a surge in COVID-19 cases. The heightened demand for point-of-care diagnostics is driven by the pandemic's impact. Furthermore, a growing awareness of self-testing and home care products is poised to contribute significantly to the expansion of the North America point-of-care diagnostics market, reflecting a broader trend toward decentralized and accessible healthcare solutions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The North America point-of-care diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for North America point-of-care diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the North America point-of-care diagnostics market. The data is available for historic period 2016-2021.

Competitive Landscape and North America Point-Of-Care Diagnostics Market Share Analysis

The North America point-of-care diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to North America point-of-care diagnostics market.

Key players operating in the North America point-of-care diagnostics market include:

• Abbott. (U.S.)
• Danaher Corporation (U.S.)
• B.D. (U.S.)
• QIAGEN (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Johnson & Johnson Private Limited (U.S.
• BIOMÉRIEUX (France)
•  Trividia Health, Inc (U.S.)
• Siemens Healthcare GmbH (Germany)
• QuidelOrtho Corporation (U.S.)
• Spectral Medical Inc (Canada)
• Abaxis (U.S.)
• Nova Biomedical (U.S.)
• Trinity Biotech (Ireland)
• Alfa Scientific Designs, Inc (U.S.)
• Bio-Rad Laboratories, Inc (U.S.) 

SKU-1810